Good News on Listing | Frost & Sullivan Assists Yisheng Biopharmaceutical Co., Ltd. in Successfully Going Public on NASDAQ (NASDAQ:YS)

Yisheng Biotech's enterprise value in this merger transaction is approximately $850 million, with approximately $36 million raised through the transaction, which will be used for the pickup truck (PIKA^®Clinical research and future commercialization of vaccines, including COVID-19 vaccines, in multiple countries.

During the process of listing in the US, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support, and highlight the issuer's competitive advantages, assisting the issuer, sponsor, and other professional intermediary institutions in completing the relevant parts of the prospectus (such as overview, competitive advantages and strategy, industry overview, business, and other important sections), helping the issuer communicate with NASDAQ and investors, assisting investors in quickly understanding the market ecosystem and competitive landscape, and providing feedback on NASDAQ's industry-related questions for the issuer.

The company is a global professional biopharmaceutical company integrating R&D, production, and sales;

The company's core product YSJA (Yishengjun'an) is the first aluminum-free adjuvant freeze-dried rabies vaccine developed in China;

The company relies on the pickup truck PICA^®Immunomodulatory technology platform with a rich clinical pipeline;

The company has a management team with rich industry experience and foresight;

According to a report by Frost & Sullivan:

Based on 2021 earnings, the company ranks fourth among Chinese human rabies vaccine providers in terms of batch issuance volume.

Rabies is a vaccine-preventable viral zoonotic disease mainly transmitted to humans through infected animals (mainly pet dogs). Rabies occurs in more than 150 countries and regions, with an estimated 59,000 deaths in 2015, over 95% of which occurred in developing countries in Asia and Africa. Without post-exposure prophylaxis (PEP), the mortality rate from rabies is nearly 100%, making human rabies vaccines crucial for preventing the disease.

The market value of China's rabies vaccine production increased from RMB 4.5 billion in 2017 to RMB 9.4 billion in 2021, with a compound annual growth rate of 20.3%. It is expected that by 2025, the market value will reach RMB 221 billion, with a compound annual growth rate of 23.8% from 2021 to 2025. By 2030, the market value of China's rabies vaccine production is expected to reach RMB 333 billion.

The Chinese market for rabies vaccine output value2017 - 2030E

Source: Frost & Sullivan report

Market participants in the Chinese rabies vaccine market include biopharmaceutical companies covering the human rabies vaccine pipeline, including Chengda Biology, Rong'an Biology, Changchun Zhuoyi, Yisheng Biology Chengdu Kanghua, etc.

According to a Frost & Sullivan report, in 2021, the number of rabies vaccine lots issued to Chinese individuals was 88 million. Based on the number of rabies vaccine lots issued to Chinese individuals, Yisheng Biological ranked fourth among Chinese competitors in 2021.

In the vaccine sector, Frost & Sullivan has served companies such as Aibo Biotech, Adimabio, Chengda Biology, Rike Biotech, Watson Biotech, and Aimeijie Vaccines.

Frost & Sullivan, integrating 62 years of global consulting experience, has dedicated 25 years to serving the booming Chinese market. With a global perspective, we help clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The healthcare industry is one of the core areas of focus for Frost & Sullivan. Over the past 20-plus years, the Frost & Sullivan team has provided financing and financial advisory services, IPO industry advice, strategic consulting, management consulting, and other services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies. Successful listings include: Meiliyuan (2373.HK), Kangfeng Biotech (6922.HK), Bo'an Biotech (6955.HK), Sidaide (1244.HK), Meihao Medical (1947.HK), Gaoshi Medical (2407.HK), Lepu Xin Tai (2291.HK), Jian Shi Technology (9877.HK), Health Yuan (JCARE.SW), Lepu Medical (LEPU.SW), Dingdang Health (9886.HK), Bai'ao Situ (2315.HK), Zhiyun Health (9955.HK), Mein Gene (6667.HK), Prenetics (PRE.NASDAQ), Yunkang Group (2325.HK), Ruike Biotech (2179.HK), Lepu Biotech (2157.HK), Clear Medical (1406.HK), Baxin An (2185.HK), Yonghe Medical (2279.HK), Kailai Ying (6821.HK), Beihai Kangcheng (1228.HK), Gusheng Tang (2273.HK), Yingpeng Technology (2251.HK), Clover Biotech (2197.HK), Minimally Invasive Robotics (2252.HK), Harmony Kamman (2256.HK), Kunbo Medical (2216.HK), Xianruida (6669.HK), Kangsheng Global (9960.HK), Yimaitong (2192.HK), Tengsheng BOPY (2137.HK), CanSino (2162.HK), Chaopu Ophthalmology (2219.HK), Guichuang Tongqiao (2190.HK), Hua Huang Medicine (0013.HK), Koi Pharmaceutical (2171.HK), Zhaoke Ophthalmology (6622.HK), Nature Pharmaceuticals (UPC.NASDAQ), Saiseng Pharmaceutical (6600.HK), Zhaoyan New Drugs (6127.HK), Novogene Health (6606.HK), ADAG Pharmaceuticals (ADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao (2161.HK), Minimally Invasive Xin Tong (2160.HK), Rui Li Medical Beauty (2135.HK), Jiaosisi Pharmaceutical (1167.HK), HepoBiotec (2142.HK), JD Health (6618.HK), Deqi Pharmaceuticals (6996.HK), Rongchang Biotech (9995.HK), WuXi AppTec (2126.HK), SinoBIO (2096.HK), Yunding New Energy (1952.HK), Jiahe Biotech (6998.HK), Zai Ding Pharmaceuticals (9688.HK), Ocular Biotech (1477.HK), Yongtai Biotech (6978.HK), Haipure Pharmaceutical (9989.HK), Kaisuo Pharmaceutical (9939.HK), Peijia Medical (9996.HK), Kangfang Biotech (9926.HK), Nuo Cheng Jian Hua (9969.HK), Tian Jing Biotech (IMAB.NASDAQ), Kanglong Chemical (3759.HK), China Antibody (3681.HK), Dongyao Pharmaceutical (1875.HK), Yasheng Medicine (6855.HK), Fuhong Hanlin (2696.HK), Hansoh Pharmaceutical (3692.HK), Mabotech (2181.HK), Fangda Holdings (1521.HK), Via Biotech (1873.HK), CStone Pharmaceuticals (2616.HK), Junshi Biotech (1877.HK), WuXi AppTec (2359.HK), Xinda Biotech (1801.HK), Hualing Medicine (2552.HK), BeiGene (6160.HK), Gilead Sciences (1672.HK), WuXi AppTec (2269.HK), China Resources Pharmaceutical (3320.HK), Yager Scientific Research Pharmaceutical (2633.HK), Hua Huang China Medicine (HCM.NASDAQ), Biotechnology (1548.HK), BBI Life Sciences (1035.HK), etc. In terms of the number of listed projects, the Frost & Sullivan healthcare team maintains an absolute leading position in Hong Kong's healthcare IPO market, consistently ranking first in market share from 2018 to 2022.

Since the listing of the first batch of companies on the Sci-tech Innovation Board in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading Sci-tech Innovation Board listed companies in the industry, including: Kangwei Century (688426.SH), Jincan Protein (688137.SH), Nuo Cheng Jianhua (688428.SH), Aopu Mai Biotech (688293.SH), MicroPort Electrophysiology (688351.SH), Mengke Pharmaceutical (688373.SH), Yifang Biotech (688382.SH), Jicui Yaokang (688046.SH), Haichuang Pharmaceutical (688302.SH), Rongchang Biotech (688331.SH), Rendu Biotech (688193.SH), Shouyao Holdings (688197.SH), Heyuan Biotech (688238.SH), Yaxin Security (688225.SH), Xidi Micro (688173.SH), Mawei Biotech (688062.SH), Yahong Medicine (688176.SH), BeiGene (688235.SH), Jiahe Meikang (688246.SH), Dizhe Medicine (688192.SH), Novogene (688105.SH), Chengda Biotech (688739.SH), Geke Micro (688728.SH), Huaxi Biotech (688363.SH), Junshi Biotech (688180.SH), Zhejiang Oncology (688266.SH), BeiGene (688177.SH), Shenzhou Cells (688520.SH), etc., and are considered one of the most powerful, professional, and influential industry research institutions in the sector. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's healthcare industry, and build a healthy future.